152 related articles for article (PubMed ID: 28224024)
21. Network analysis of liver cancer: a system biology approach.
Arjmand B; Jahani Sherafat S; Rezaei Tavirani M; Hamzeloo Moghadam M; Abbasi MA
Gastroenterol Hepatol Bed Bench; 2023; 16(3):319-325. PubMed ID: 37767318
[TBL] [Abstract][Full Text] [Related]
22. Nonalcoholic steatohepatitis in nonalcoholic fatty liver disease patients of Bangladesh.
Alam S; Noor-E-Alam SM; Chowdhury ZR; Alam M; Kabir J
World J Hepatol; 2013 May; 5(5):281-7. PubMed ID: 23717739
[TBL] [Abstract][Full Text] [Related]
23. [A new attempt with lipoprotein lipase agonists in the treatment of nonalcoholic steatohepatitis].
Chen YH; Zhan Z; Hu P; Ren H; Peng ML
Zhonghua Gan Zang Bing Za Zhi; 2019 Jul; 27(7):533-540. PubMed ID: 31357780
[No Abstract] [Full Text] [Related]
24. Bioinformatics Analysis Explores Potential Hub Genes in Nonalcoholic Fatty Liver Disease.
Wu C; Zhou Y; Wang M; Dai G; Liu X; Lai L; Tang S
Front Genet; 2021; 12():772487. PubMed ID: 34777484
[No Abstract] [Full Text] [Related]
25. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Sugimoto K; Inui H; Fukusato T
World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
[TBL] [Abstract][Full Text] [Related]
26. Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects.
Ampuero J; Aller R; Gallego-Durán R; Crespo J; Abad J; González-Rodríguez Á; Gómez-Camarero J; Caballería J; Lo Iacono O; Ibañez L; García-Samaniego J; Martín-Mateos R; Francés R; Fernández-Rodríguez C; Diago M; Soriano G; Andrade RJ; Latorre R; Jorquera F; Morillas RM; Escudero D; Estévez P; Hernández-Guerra M; Augustín S; Pareja-Megia MJ; Banales JM; Aspichueta P; Benlloch S; Rosales JM; Salmerón J; Turnes J; Romero-Gómez M;
Liver Int; 2021 Sep; 41(9):2076-2086. PubMed ID: 33896100
[TBL] [Abstract][Full Text] [Related]
27. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
[No Abstract] [Full Text] [Related]
28. Fibrinogen-like protein 2 aggravates nonalcoholic steatohepatitis via interaction with TLR4, eliciting inflammation in macrophages and inducing hepatic lipid metabolism disorder.
Hu J; Wang H; Li X; Liu Y; Mi Y; Kong H; Xi D; Yan W; Luo X; Ning Q; Wang X
Theranostics; 2020; 10(21):9702-9720. PubMed ID: 32863955
[No Abstract] [Full Text] [Related]
29. Key factors and potential drug combinations of nonalcoholic steatohepatitis: Bioinformatic analysis and experimental validation-based study.
Fan GH; Wei RL; Wei XY; Zhang CZ; Qi ZT; Xie HY; Zheng SS; Xu X
Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):433-451. PubMed ID: 34233850
[TBL] [Abstract][Full Text] [Related]
30. Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum.
Hardy T; Oakley F; Anstee QM; Day CP
Annu Rev Pathol; 2016 May; 11():451-96. PubMed ID: 26980160
[TBL] [Abstract][Full Text] [Related]
31. Serum cytokeratin 18 fragment level as a noninvasive biomarker for non-alcoholic fatty liver disease.
Aida Y; Abe H; Tomita Y; Nagano T; Seki N; Sugita T; Itagaki M; Ishiguro H; Sutoh S; Aizawa Y
Int J Clin Exp Med; 2014; 7(11):4191-8. PubMed ID: 25550930
[TBL] [Abstract][Full Text] [Related]
32. Nonalcoholic Fatty Liver Disease vs. Nonalcoholic Steatohepatitis: Pathological and Clinical Implications.
Boutari C; Lefkos P; Athyros VG; Karagiannis A; Tziomalos K
Curr Vasc Pharmacol; 2018; 16(3):214-218. PubMed ID: 28676025
[TBL] [Abstract][Full Text] [Related]
33. Irisin in patients with nonalcoholic fatty liver disease.
Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
[TBL] [Abstract][Full Text] [Related]
34. Network pharmacology analysis of Chaihu Lizhong Tang treating non-alcoholic fatty liver disease.
Zhang M; Yuan Y; Zhou W; Qin Y; Xu K; Men J; Lin M
Comput Biol Chem; 2020 Jun; 86():107248. PubMed ID: 32208163
[TBL] [Abstract][Full Text] [Related]
35. Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
Manne V; Handa P; Kowdley KV
Clin Liver Dis; 2018 Feb; 22(1):23-37. PubMed ID: 29128059
[TBL] [Abstract][Full Text] [Related]
36. Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status.
Stein LL; Dong MH; Loomba R
Adv Ther; 2009 Oct; 26(10):893-907. PubMed ID: 19921118
[TBL] [Abstract][Full Text] [Related]
37. Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis.
Xu G; Wang YM; Ying MM; Chen SD; Li ZR; Ma HL; Zheng MH; Wu J; Ding C
Clin Mol Hepatol; 2021 Apr; 27(2):329-345. PubMed ID: 33465844
[TBL] [Abstract][Full Text] [Related]
38. Nonalcoholic steatohepatitis and insulin resistance in children.
Arata M; Nakajima J; Nishimata S; Nagata T; Kawashima H
World J Diabetes; 2014 Dec; 5(6):917-23. PubMed ID: 25512797
[TBL] [Abstract][Full Text] [Related]
39. Yellow loosestrife (Lysimachia vulgaris var. davurica) ameliorates liver fibrosis in db/db mice with methionine- and choline-deficient diet-induced nonalcoholic steatohepatitis.
Son YJ; Jung DS; Shin JM; Kim M; Yoo G; Nho CW
BMC Complement Med Ther; 2021 Jan; 21(1):44. PubMed ID: 33494735
[TBL] [Abstract][Full Text] [Related]
40. Activation of Insulin-PI3K/Akt-p70S6K Pathway in Hepatic Stellate Cells Contributes to Fibrosis in Nonalcoholic Steatohepatitis.
Cai CX; Buddha H; Castelino-Prabhu S; Zhang Z; Britton RS; Bacon BR; Neuschwander-Tetri BA
Dig Dis Sci; 2017 Apr; 62(4):968-978. PubMed ID: 28194671
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
